日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications

司库奇尤单抗对传统心血管危险因素和炎症生物标志物的影响:三个适应症汇总数据的事后分析

Merola, Joseph F; McInnes, Iain B; Deodhar, Atul A; Dey, Amit K; Adamstein, Nicholas H; Quebe-Fehling, Erhard; Aassi, Maher; Peine, Michael; Mehta, Nehal N

Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials

为期 12 周的司库奇尤单抗治疗对中重度银屑病始终有效,且不受既往生物制剂和非生物制剂系统治疗的影响:六项随机试验的事后分析

Hampton, P; Halliday, A; Aassi, M; Subramanian, S; Jain, M; Griffiths, C E M

Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study

在欧洲真实世界环境中,司库奇尤单抗用于治疗中重度银屑病、银屑病关节炎和强直性脊柱炎患者:SERENA 研究的基线数据

Kiltz, Uta; Sfikakis, Petros P; Gaffney, Karl; Sator, Paul-Gunther; von Kiedrowski, Ralph; Bounas, Andreas; Gullick, Nicola; Conrad, Curdin; Rigopoulos, Dimitris; Lespessailles, Eric; Romanelli, Marco; Ghislain, Pierre-Dominique; Brandt-Jürgens, Jan; Rashkov, Rasho; Aassi, Maher; Orsenigo, Roberto; Perella, Chiara; Pournara, Effie; Gathmann, Sven; Jagiello, Piotr; Veit, Justyna; Augustin, Matthias

Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study

全球比较观察研究:以抗肿瘤坏死因子或托珠单抗作为一线生物制剂治疗类风湿性关节炎

Choy, Ernest H; Bernasconi, Corrado; Aassi, Maher; Molina, Jose Fernando; Epis, Oscar Massimiliano

Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study

ACT-RAY 研究 2 年时的临床和影像学结果,以及在第二年和第三年持续缓解后停用托珠单抗的影响

Huizinga, T W J; Conaghan, Philip G; Martin-Mola, Emilio; Schett, Georg; Amital, Howard; Xavier, Ricardo M; Troum, Orrin; Aassi, Maher; Bernasconi, Corrado; Dougados, Maxime

Evaluation of the Disease Activity Score in Twenty-Eight Joints-Based Flare Definitions in Rheumatoid Arthritis: Data From a Three-Year Clinical Trial

基于28个关节的类风湿关节炎疾病活动度评分评估:一项为期三年的临床试验数据

Dougados, Maxime; Huizinga, Tom W J; Choy, Ernest H; Bingham, Clifton O 3rd; Aassi, Maher; Bernasconi, Corrado

Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice

托珠单抗单药治疗或联合使用改善病情抗风湿药治疗对既往治疗反应不佳的类风湿关节炎患者:一项接近临床实践的开放标签研究

Bykerk, Vivian P; Östör, Andrew J K; Alvaro-Gracia, José; Pavelka, Karel; Román Ivorra, José Andrés; Graninger, Winfried; Bensen, William; Nurmohamed, Michael T; Krause, Andreas; Bernasconi, Corrado; Aassi, Maher; Sibilia, Jean

Erratum to: Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice

更正:托珠单抗单药治疗或联合其他改善病情抗风湿药物治疗对既往治疗反应不佳的类风湿关节炎患者的比较:一项接近临床实践的开放标签研究

Bykerk, Vivian P; Östör, Andrew J K; Alvaro-Gracia, José; Pavelka, Karel; Ivorra, José Andrés Román; Graninger, Winfried; Bensen, William; Nurmohamed, Michael T; Krause, Andreas; Bernasconi, Corrado; Aassi, Maher; Sibilia, Jean